Skip to Main Content

Hudson Lab

Inflammation in metastatic disease

Contact Us

Investigator / Contact Person Barry Hudson


My lab's research is focused on understanding the inflammatory mechanisms underlying breast cancer and translating these basic observations to human clinical studies. Our research efforts have focused on the inflammatory role of the Receptor for Advanced Glycation End-products (RAGE) and its ligands (AGEs, s100s and HMGB1) in diabetes and cancer.
Most recently, my laboratory has made important observations on the role RAGE and its ligands in the pathogenesis of breast cancer progression and metastasis. We have also found that blocking RAGE signaling using a novel therapeutic, inhibits metastasis in murine models (revision submitted to Oncogene). This work has also won a number of recent awards for graduate students in my lab including the Department of Medicine Research Day and the Annual Zubrod Cancer Research Poster competitions. Currently were are funded by a number of awards including a Susan G. Komen Career Development award.

Our current goals are to:
1. Determine the specific cell types in the tumor microenvironment by which RAGE / RAGE-ligands influence cancer progression and metastasis, and determine the critical RAGE ligands involved.
2. Develop further RAGE therapeutics for clinical use in breast and other cancers.
3. Determine whether obesity and diabetes drive the increased risk of cancer progression and metastasis through RAGE signaling.

To address these research questions, our lab uses cell and animal models, genetic approaches and drug inhibitors, and human clinical samples. We are highly collaborative with other groups at UM and other US institutes including Marc Lippman's breast cancer research group. Our future goals are to understand how inflammation is critical for breast cancer metastasis and further explore therapeutic strategies to direct against RAGE in breast and other cancers.